Vitamin D for Sickle-cell Respiratory Complications
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This study aims to answer the question whether oral vitamin D supplementation can decrease lung complications in children and adolescents with sickle cell disease. Lung complications are the leading causes of morbidity and of death in sickle cell disease. Infections and increased inflammation play important roles in the development of the lung problems in sickle cell disease. Emerging evidence shows that vitamin D helps the immune system to fight infection and to control inflammation and could potentially help prevent respiratory complications in patients with sickle cell disease. The investigators hypothesize that oral vitamin D3, 100,000 IU (2.5 mg), given once a month to a group of children and adolescents with sickle cell disease, will reduce the rate of respiratory events (infection, asthma exacerbation and acute chest syndrome) compared to the rate in a group given standard dose oral vitamin D3, 12,000 IU (0.3 mg) given once a month.
| Condition | Intervention | Phase |
|---|---|---|
|
Sickle Cell Disease Vitamin D Deficiency Acute Chest Syndrome Asthma Respiratory Infections |
Drug: Vitamin D3 |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | Vitamin D for Sickle-cell Respiratory Complications |
- Respiratory events (defined as respiratory infection, acute asthma exacerbation, and acute chest syndrome) [ Time Frame: Every year for 2 years ] [ Designated as safety issue: No ]
- Pulmonary function tests [ Time Frame: Every year for 2 years ] [ Designated as safety issue: No ]
- Immune function [ Time Frame: Every 6 months for 2 years ] [ Designated as safety issue: No ]Serum cytokines to measure T-cell effector and regulatory function Measures of systemic inflammation (hs-CRP, WBC, platelets)
- Bone function and bone turnover markers [ Time Frame: Every 6 months for 2 years ] [ Designated as safety issue: No ]Intact parathyroid hormone Serum C-terminal telopeptides of Type I collagen (CTX) Aminoterminal propeptide of Type 1 procollagen (P1NP)
- Muscle strength (Hand grip) [ Time Frame: Every year for 2 years ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 130 |
| Study Start Date: | December 2011 |
| Estimated Study Completion Date: | December 2015 |
| Estimated Primary Completion Date: | December 2014 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Vitamin D3 100,000 IU
Oral vitamin D3, 100,000 IU [2.5 mg] given once a month
|
Drug: Vitamin D3
Vitamin D3 100,000 IU orally once a month
Other Name: Cholecalciferol
|
|
Active Comparator: Vitamin D3 12,000 IU
Standard dose oral vitamin D3 12,000 IU [0.3 mg] given once a month
|
Drug: Vitamin D3
Vitamin D3 12,000 IU orally once a month
Other Name: Cholecalciferol
|
Detailed Description:
This study will be a Phase 2 double-blind randomized clinical trial in 80 patients with sickle cell disease, ages 3 to 20 years-old, comparing a 2-year monthly oral dose of vitamin D3, 100,000 IU (equivalent to 3,300 IU/day) to a standard monthly dose, 12,000 IU (400 IU/day) in reducing the rate of respiratory events (defined as respiratory infections, acute asthma exacerbation, and the acute chest syndrome) in children and adolescents with sickle cell disease in comparison with the rates of respiratory events over a baseline period of one year.
Eligible participants (130 patients) will initially be screened to determine their blood vitamin D levels (serum 25-hydroxyvitamin D). Those with 25-hydroxyvitamin D levels between 5 and 60 ng/mL will be eligible for randomization. At study entry, blood and urine samples will be collected for routine and special blood tests including tests on immune function, inflammation, and bone function. Children above 5 years old will also have lung function and muscle strength tests. Participants will be followed once a month to administer the study medication (oral vitamin D3) and to monitor any side effects from the study medication by history, examination and blood and urine tests. After 12 and 24 months of therapy, the same study procedures at study entry will be repeated.
This study could help establish oral vitamin D3 as a simple, low cost treatment to reduce respiratory complications in children and adolescents with sickle cell disease.
Eligibility| Ages Eligible for Study: | 3 Years to 20 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Diagnosis of sickle cell disease (HbSS, SC, S Beta-thalassemia)
- Age 3 to 20 years old
Exclusion Criteria:
- Patient (or parent or guardian) unwilling or unable to provide written informed consent (and assent, if applicable)
- Patient unable or unwilling to comply with requirements of the clinical trial
- Participation in other therapeutic clinical trial
- Current diagnosis of rickets
- History of hypercalcemia or diagnosis of any medical condition associated with hypercalcemia, including primary hyperparathyroidism, malignancy, sarcoidosis, tuberculosis, granulomatous disease, familial hypocalciuric hypercalcemia
- Current use of corticosteroids, excluding inhaled steroids
- Current use of anticonvulsants (phenytoin, phenobarbital, carbamazepine)
- Therapy with thiazide diuretics or lithium carbonate
- Known liver or renal disease
- Patients taking medications for pulmonary complications of sickle cell disease not on a stable dose of medications, as defined by a change in medications or doses within the three months prior to study entry
- Patients on chronic red blood cell transfusion therapy
- Absence of baseline record of respiratory events (respiratory infections, asthma exacerbations, episodes of acute chest syndrome) for the preceding year
- Pregnancy
Contacts and Locations| Contact: Margaret T Lee, MD | 212 305 2466 | ml653@columbia.edu |
| Contact: Susan Rivera, RN | 212 342 0273 | sr2999@columbia.edu |
| United States, New York | |
| Columbia University Medical Center | Recruiting |
| New york, New York, United States, 10032 | |
| Contact: Margaret T Lee, MD 212-305-2466 ml653@columbia.edu | |
| Contact: Genia Billote, RN, MPH 212 342 0262 gbb2101@columbia.edu | |
| Principal Investigator: Gary Brittenham, MD | |
| Principal Investigator: Margaret T Lee, MD | |
| Principal Investigator: | Gary Brittenham, MD | Columbia University |
| Principal Investigator: | Margaret T Lee, MD | Columbia University |
More Information
No publications provided
| Responsible Party: | Gary M Brittenham, MD, James A. Wolff Professor of Pediatrics, Columbia University |
| ClinicalTrials.gov Identifier: | NCT01443728 History of Changes |
| Other Study ID Numbers: | AAAE3244 |
| Study First Received: | September 27, 2011 |
| Last Updated: | February 11, 2013 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by Columbia University:
|
sickle cell disease acute chest syndrome respiratory complications vitamin D |
Additional relevant MeSH terms:
|
Vitamin D Ergocalciferols Anemia, Sickle Cell Asthma Respiratory Tract Infections Vitamin D Deficiency Acute Chest Syndrome Anemia, Hemolytic, Congenital Anemia, Hemolytic Anemia Hematologic Diseases Hemoglobinopathies Genetic Diseases, Inborn Bronchial Diseases Respiratory Tract Diseases |
Lung Diseases, Obstructive Lung Diseases Respiratory Hypersensitivity Hypersensitivity, Immediate Hypersensitivity Immune System Diseases Infection Avitaminosis Deficiency Diseases Malnutrition Nutrition Disorders Respiration Disorders Cholecalciferol Vitamins Micronutrients |
ClinicalTrials.gov processed this record on May 16, 2013